14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ICCC vs SRZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas SRZN carries 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin).
Growth vs. Quality Trade-Off: ICCC earns the overall head-to-head edge with a stronger Unified Composite Score (43.8/100 HOLD vs. SRZN 34.3/100 SELL) and 0.24β · 46% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ICCC vs SRZN Key Questions & Quantitative Answers
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas SRZN carries 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin). Growth vs. Quality Trade-Off: ICCC earns the overall head-to-head edge with a stronger Unified Composite Score (43.8/100 HOLD vs. SRZN 34.3/100 SELL) and 0.24β · 46% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
SRZN leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ICCC cumulative revenue shifted +200.0% while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.
ICCC screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus SRZN (-62.8% ROE) capital efficiency.
In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.